Organisation paid for research Program year 2022 Source: CMS Open Payments

Clinical Research Services, Incorporated

Neither a doctor nor a teaching hospital

Research payments

$797,846

8 payments

Through program year 2022, Clinical Research Services, Incorporated is reported as receiving $797,846 in research payments, across 8 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2022	Research	$143,649	3
2021	Research	$516,438	3
2020	Research	$137,759	2

Breakdown

Who paid Research payments · program years 2020–2022

Celgene Corporation $797,846 8 payments

Studies the money was for Research payments · program years 2020–2022

A Phase 1 Open-Label Single-Dose Study to Assess t $303,117 1 payment
A Phase 1, Open-Label, Single Dose Study to Assess $166,042 1 payment
A Phase 1 Open-Label Single-Dose Study to Assess t - A Phase 1 Open-Label Single-Dose Study to Assess the Pharmacokinetics of Enasidenib (CC 90007) in Subjects with Mild, Moderate and Severe Hepatic Impairment $115,366 1 payment
A Phase 1, Open-Label, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Fedratinib in Subjects with Moderate and Severe Hepatic Impairment Compared with Healthy Subjects (BMS Study Number: CA054-P06) $101,446 1 payment
A Phase 1 Open-label, Single-dose Study to Assess $47,279 1 payment
An Observational Follow-on Study to Describe the Pharmacogenetics of the CC-90007-CP-003 Study Cohort $36,314 1 payment
Hepatic (RPC-1063-CP-004) (BMS Study Number: IM047-P06) - A Phase 1, Open-Label, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Ozanimod in Subjects with Mild, Moderate or Severe Hepatic Impairment Compared with Healthy Subj $21,975 1 payment
A Phase 1, Open-Label, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Fedratinib in Subjects with Moderate and Severe Hepatic Impairment Compared with Healthy Subjects $6,308 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.